Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H2 2016, provides an overview of the Hypereosinophilic Syndrome (Hematological Disorders) pipeline landscape.
The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (≥ 1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical eosinophilia, or cancer) have been ruled out.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypereosinophilic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Phase II stages are 1 and 4 respectively.Hypereosinophilic Syndrome.
Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypereosinophilic Syndrome (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypereosinophilic Syndrome (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypereosinophilic Syndrome (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypereosinophilic Syndrome (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Bristol-Myers Squibb Company
GlaxoSmithKline Plc
Knopp Biosciences LLC
Kyowa Hakko Kirin Co Ltd
Stemline Therapeutics Inc
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hypereosinophilic Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Hypereosinophilic Syndrome - Overview 7
Hypereosinophilic Syndrome - Therapeutics under Development by Companies 8
Hypereosinophilic Syndrome - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Hypereosinophilic Syndrome - Products under Development by Companies 11
Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development 12
Bristol-Myers Squibb Company 12
GlaxoSmithKline Plc 13
Knopp Biosciences LLC 14
Kyowa Hakko Kirin Co Ltd 15
Stemline Therapeutics Inc 16
Hypereosinophilic Syndrome - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
benralizumab - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
dasatinib - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
dexpramipexole dihydrochloride - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
mepolizumab - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
SL-401 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Hypereosinophilic Syndrome - Dormant Projects 48
Hypereosinophilic Syndrome - Product Development Milestones 49
Featured News & Press Releases 49
Mar 13, 2014: Knopp Biosciences Broadens Collaboration with NIH to Investigate Eosinophil-Lowering Effects of Dexpramipexole 49
Jan 08, 2014: Knopp Biosciences and NIH to Collaborate in Evaluating Dexpramipexole in Patients with Hypereosinophilic Syndrome 49
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52
List of Tables
Number of Products under Development for Hypereosinophilic Syndrome, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Hypereosinophilic Syndrome - Pipeline by Bristol-Myers Squibb Company, H2 2016 12
Hypereosinophilic Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016 13
Hypereosinophilic Syndrome - Pipeline by Knopp Biosciences LLC, H2 2016 14
Hypereosinophilic Syndrome - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 15
Hypereosinophilic Syndrome - Pipeline by Stemline Therapeutics Inc, H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Stage and Target, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Hypereosinophilic Syndrome - Dormant Projects, H2 2016 48
List of Figures
Number of Products under Development for Hypereosinophilic Syndrome, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Top 10 Targets, H2 2016 18
Number of Products by Stage and Top 10 Targets, H2 2016 18
Number of Products by Top 10 Mechanism of Actions, H2 2016 20
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 20
Number of Products by Routes of Administration, H2 2016 22
Number of Products by Stage and Routes of Administration, H2 2016 22
Number of Products by Molecule Types, H2 2016 24
Number of Products by Stage and Molecule Types, H2 2016 24
